BioLife Solutions, Inc. (BLFS)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 56 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
BioLife Solutions beat both the top and bottom line in the second fiscal quarter of 2026, reported Aug. 6, 2026, as revenue rose about 12% to roughly $28.5 million and EPS of $0.04 topped the $0.03 estimate by about 47%; the per-share result also improved from -$0.33 a year ago. Revenue also edged the $27.8 million consensus by roughly 2%, while gross profit came in at about $18.3 million with gross margin near 64%. Operating cash flow was about $5.9 million. Consensus for the next period calls for EPS of $0.01 on revenue of $29.0 million.
About BioLife Solutions, Inc.
BioLife Solutions, Inc. (NASDAQ: BLFS) develops and sells tools used in biopreservation and handling for the healthcare field, particularly cell and gene therapy workflows. Across media, thawing devices, shipping systems, freezer equipment, and storage services, it generated $96.2 million of revenue in FY2025.
Today's Snapshot
BLFS closed 1.3% below yesterday's close, while its sector was flat. Volume was about a quarter more than its usual level.
Trading Volume
Above 10d avg 935.3K
1.2M
vs S&P 500 Today
Underperforming Market
-0.85%
Updated: September 9, 2026 at 20:27 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$27.64 - $35.70Buy
- RSI (14)50.38Neutral
- Stochastic %K (14, 3, 3)11.72Buy
- MACD Level (12, 26)0.75Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.